Conferences

BCAN 2019: Genomics in Bladder Cancer August 10, 2019

BCAN 2019: Integrated Mutation Profiling of Actionable Cancer Targets (IMPACT) August 10, 2019

BCAN 2019: The Biomarker Discovery Process for Bladder Cancer August 10, 2019

BCAN 2019: FDA Collaboration with the Bladder Cancer Community August 9, 2019

BCAN 2019: Proteogenomic Characterization of Muscle-invasive Bladder Cancer August 9, 2019

BCAN 2019: Race and Guideline Based Treatment in Bladder Cancer August 9, 2019

BCAN 2019: FDA Approval of Therapies in the Context of BCG Shortages and Alternative Therapies August 9, 2019

BCAN 2019: Diagnostic Approach in Clinically Node Positive Bladder Cancer August 9, 2019

BCAN 2019: FDA Collaboration in Adjuvant Trials in Muscle Invasive Bladder Cancer August 9, 2019

BCAN 2019: Palliative Care Use Amongst Patients With Bladder Cancer August 9, 2019

BCAN 2019: Radiographic Consideration Prior to Clinical Trial Enrollment August 9, 2019

BCAN 2019: The Introduction of Palliative Care in Bladder Cancer August 9, 2019

BCAN 2019: How Urology Can Improve Implementation and Dissemination of Palliative Care in Bladder Cancer August 9, 2019

Collaborating to Move Research Forward - 2019 BCAN Think Tank August 8, 2019

ASCO 2019: Vofatamab in Combination with Pembrolizumab in WT Metastatic Urothelial Carcinoma: FIERCE-22 June 5, 2019

ASCO 2019: IMmotion151 Subgroup Analysis: Atezolizumab + Bevacizumab versus Sunitinib in Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Histology June 5, 2019

ASCO 2019: Patient-Reported Outcomes in IMmotion150: Atezolizumab alone or with Bevacizumab versus Sunitinib in First-Line Metastatic Renal Cell Carcinoma June 5, 2019

ASCO 2019: CheckMate 214 Post-Hoc Analyses of Nivolumab plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma with Sarcomatoid Features June 5, 2019

ASCO 2019: Efficacy of Immune Checkpoint Inhibitors and Genomic Characterization of Sarcomatoid and/or Rhabdoid Metastatic Renal Cell Carcinoma June 5, 2019

ASCO 2019: Biomarkers of Outcomes in a Randomized Phase II trial of first-line paclitaxel, ifosfamide, and Cisplatin versus Bleomycin, Etoposide, and Cisplatin for Intermediate- and Poor-Risk Germ Cell Tumors June 5, 2019

Page 1 of 304

E-Newsletters

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.